The CXCR4 antagonist plerixafor enhances the effect of rituximab in diffuse large B-cell lymphoma cell lines

BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) is an aggressive disease with variable clinical outcome, accounting for at least 25-30 % of adult non-Hodgkin lymphomas. Approximately one third of DLBCL patients are not cured by the currently used treatment regimen, R-CHOP. Hence, new treatment str...

Descripción completa

Detalles Bibliográficos
Autores principales: Reinholdt, Linn, Laursen, Maria Bach, Schmitz, Alexander, Bødker, Julie Støve, Jakobsen, Lasse Hjort, Bøgsted, Martin, Johnsen, Hans Erik, Dybkær, Karen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4908729/
https://www.ncbi.nlm.nih.gov/pubmed/27307990
http://dx.doi.org/10.1186/s40364-016-0067-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4908729/
https://www.ncbi.nlm.nih.gov/pubmed/27307990
http://dx.doi.org/10.1186/s40364-016-0067-2

Ejemplares similares